FY2024 EPS Estimates for Femasys Decreased by HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – HC Wainwright lowered their FY2024 EPS estimates for shares of Femasys in a research note issued on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.84) per share for the year, down from their prior estimate of ($0.78). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Separately, Chardan Capital cut their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday.

Femasys Stock Down 2.8 %

Shares of FEMY opened at $0.95 on Friday. The stock has a fifty day simple moving average of $1.16 and a two-hundred day simple moving average of $1.14. The company has a quick ratio of 5.93, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $21.82 million, a PE ratio of -1.18 and a beta of -2.83. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40.

Institutional Investors Weigh In On Femasys

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CM Management LLC increased its position in shares of Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after acquiring an additional 25,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after purchasing an additional 17,473 shares during the last quarter. XTX Topco Ltd increased its holdings in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the last quarter. Finally, Aljian Capital Management LLC purchased a new stake in Femasys in the third quarter valued at approximately $27,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.